Plackett–Burman Design for the development of acetylated cashew gum nanoparticles loaded with naproxen: In vivo evaluation Jucielma Silva de Lima, Jéssica Cavalcante Martins, Tarcísio Mendes Silva, Marcela Albuquerque de Oliveira, Marcilene Souza da Silva, Silvania Tavares Paz, Eryvelton de Souza Franco, Ivone Antônia de Souza, Durcilene Alves da Silva, Amanda Damasceno Leão, Luise Lopes Chaves, Antônia Carla de Jesus Oliveira, José Lamartine Soares-Sobrinho, Monica Felts de La Roca Soares Journal of Drug Delivery Science and Technology, 2026
Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue Pedro Lucas Machado Magalhães, Anderson Matheus Pereira da Silva, Mariana Letícia de Bastos Maximiano, João Vitor Andrade Fernandes, Dillan Cunha Amaral, Alice de Aquino Tavares Fortes, Helvécio Neves Feitosa Filho, Luiza de Oliveira Silva, Beatriz Dias da Silva Teixeira, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia Journal of Clinical Psychopharmacology, 2026 Background: Coenzyme Q10 (CoQ10) is a mitochondrial cofactor with antioxidant and anti-inflammatory properties that may counteract mechanisms implicated in depression, such as oxidative stress and mitochondrial dysfunction. We evaluated the efficacy of CoQ10 supplementation on depressive symptoms and fatigue in patients with depression, whether as a primary disorder or in the context of underlying medical illness. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Randomized controlled trials comparing CoQ10 with placebo or standard treatment in patients diagnosed with depression were eligible, independent of concomitant medical conditions. Outcomes included changes in depressive symptoms and fatigue. Data were pooled using random-effects models, with standardized mean differences (SMD) and 95% CIs. Heterogeneity was assessed with the I 2 statistic, and sensitivity analyses were performed using a leave-one-out approach. Results: Five RCTs with 474 participants were included. Three trials enrolled patients with depression associated with significant medical conditions—multiple sclerosis, breast cancer, and polycystic ovary syndrome—while 2 included patients with primary depressive disorders (major depression and bipolar disorder). CoQ10 supplementation significantly reduced depressive symptoms compared with control (SMD: −0.68; 95% CI: −1.02 to −0.33; P <0.01; I 2 =58%), with consistent results across rating scales. Sensitivity analysis indicated that heterogeneity was largely driven by a single study. No significant benefit was observed for fatigue (SMD: −0.33; 95% CI: −1.38 to 0.72; P =0.54; I 2 =89%), based on only 2 trials. Conclusions: CoQ10 supplementation may confer moderate improvement in depressive symptoms across diverse populations. However, the evidence for fatigue remains inconclusive.
Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer’s Disease: A Systematic Review, Meta-Analysis and Meta-Regression Anderson Matheus Pereira da Silva, Gabriel Caruso Novaes Tudella, Ocilio Ribeiro Gonçalves, Filipe Virgilio Ribeiro, Maria Antonia Oliveira Machado Pereira, Maria da Vitória Santos do Nascimento, Bernardo Vieira Nogueira, Diogo Haddad Santos, Fábio Henrique de Gobbi Porto, Poul F. Høilund-Carlsen, Filipe Silveira Duarte, George Perry, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia Drugs, 2026
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression Anderson Matheus Pereira da Silva, Ocilio de Deus, Leonardo Januário Campos Cardoso, Filipe Virgilio Ribeiro, Patrick Froelich Meldola, Isabelle Rodrigues Menezes, Mariana Lee Han, Daniel Gonçalves Quiroga, Kelson James Almeida, Diogo Haddad Santos, George Perry, Poul F. Høilund-Carlsen, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia Expert Opinion on Biological Therapy, 2026 BACKGROUND: Alzheimer's disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. However, the efficacy and safety of anti-β-amyloid monoclonal antibodies remain debated. METHODS: We systematically searched PubMed, Embase, and Cochrane databases for RCTs comparing anti-β-amyloid monoclonal antibodies with placebo in early-stage AD. Eligible trials enrolled participants with biomarker-supported AD and reported global, cognitive, or safety outcomes, including the CDR-SB, ADAS-Cog 13/14, ARIA, and brain volumetric measures. RESULTS: Six RCTs including 7837 participants were analyzed. Mean age ranged from 69.8 to 75.4 years, and 57.4% were APOE ε4 carriers. Anti-β-amyloid therapy was associated with small differences in global and cognitive outcomes, best described as a modest slowing of decline on the CDR-SB and ADAS-Cog scales. Treatment was associated with increased risks of ARIA-E (RR, 9.40; 95% CI, 6.98-12.66) and ARIA-H (RR, 2.40; 95% CI, 2.08-2.78), as well as greater ventricular enlargement and hippocampal atrophy. CONCLUSION: In early AD, anti-β-amyloid monoclonal antibodies are associated with modest slowing of decline accompanied by increased ARIA risk and unfavorable structural brain changes, limiting clinical applicability. PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD420251071393.
Efficacy, Immunogenicity, Safety, and Tolerability of AADvac1 in Alzheimer Disease Anderson M. Pereira da Silva, Luciano Falcão Carneiro Filho, Filipe Virgilio Ribeiro, Isabelle Rodrigues Menezes, Marianna Leite, Elizabeth Honorato de Farias, Maria da Vitória Nascimento, Anderson Silva Corin, Daniel Gonçalves Quiroga, Eryvelton de Souza Franco, Maria B. de Sousa Maia Alzheimer Disease and Associated Disorders, 2025 Background: This systematic review and meta-analysis aimed to evaluate the efficacy, humoral immunogenicity, safety, and tolerability of AADvac1 an active tau-targeted immunotherapy in patients with Alzheimer disease (AD) confirmed by amyloid and tau pathology. Methods: We searched MEDLINE, Embase, Scopus, and CENTRAL from inception to March 2025 for randomized placebo-controlled trials assessing AADvac1 in AD. Eligible studies included adult patients with biomarker-confirmed AD. Risk of bias was assessed using the Cochrane RoB 2 tool. Meta-analyses were conducted using random-effects models. Results: Five trials (n=667) were included, of which 391 received AADvac1 and 276 received placebo. Pooled analyses showed a robust IgG response (IgG seroconversion rate: 99%, 95% CI: 95%-100%) with predominance of IgG1 and IgG3 subclasses. AADvac1 did not improve MMSE (MD: –0.49; 95% CI: –2.40 to 1.41) but showed trends favoring improvement in ADAS-Cog11 and verbal fluency. The vaccine was well tolerated, with injection site reactions being the most frequent adverse event. No increased risk of serious infections, cerebral edema, or mortality was observed. Conclusions: AADvac1 demonstrates robust immunogenicity and an acceptable safety profile in early-phase trials. Cognitive benefits remain inconclusive. Larger, long-term trials are needed to confirm its clinical efficacy and long-term safety in AD.
Effect of a semisolid formulation of Linum usitatissimum L. (linseed) oil on the repair of skin wounds Eryvelton de Souza Franco, Camilla Maria Ferreira de Aquino, Paloma Lys de Medeiros, Liriane Baratella Evêncio, Alexandre José da Silva Góes, Maria Bernadete de Souza Maia Evidence Based Complementary and Alternative Medicine, 2012 The purpose of this study was to investigate the effects of a semisolid formulation of linseed oil, SSFLO (1%, 5%, or 10%) orin naturalinseed oil on skin wounds of rats. We used wound models, incisional and excisional, to evaluate, respectively, the contraction/reepithelialization of the wound and resistance to mechanical traction. The groups (n=6) treated with SSFLO (1% or 5%) began the process of reepithelialization, to a significant extent (P<.05), on the sixth day, when compared to the petroleum jelly control group. On 14th day for the groups treated with SSFLO (1% or 5%), 100% reepithelialization was found, while in the petroleum jelly control group, this was only 33.33%. Our study showed that topical administration of SSFLO (1% or 5%) in excisional wounds allowed reepithelialization in 100% of treated animals. Therefore, a therapeutic potential of linseed oil, when used at low concentrations in the solid pharmaceutical formulations, is suggested for the process of dermal repair.
